Skip to content
Biodatica
Start free

Genmab

Phoenix, Arizona

OncologyPhase IIIListed · GMAB

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer

5d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 1, 2026

    Left-sided Colorectal Cancer · NOT_YET_RECRUITING · sponsor: Genmab · Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer

    ClinicalTrials.gov · NCT07702032 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jul 1, 2026

    Platinum-Sensitive Ovarian Cancer, Ovarian Cancer · NOT_YET_RECRUITING · sponsor: Genmab · Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

    ClinicalTrials.gov · NCT07564141 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    May 14, 2019

    Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Genmab · GEN1046 Safety Trial in Patients With Malignant Solid Tumors

    ClinicalTrials.gov · NCT03917381 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources